Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to assess the efficacy of idebenone in delaying the loss of respiratory function in patients with DMD receiving concomitant glucocorticoid steroids


Clinical Trial Description

The SIDEROS trial is a randomized, placebo controlled, parallel group study of the efficacy of idebenone in delaying the loss of respiratory function, whilst also monitoring safety and tolerability of idebenone in at least 266 DMD patients taking stable dose of concomitant glucocorticoid steroids. The study treatment period will be 18 months/ 78 weeks and the idebenone dose will be 900 mg/day. Participants can use deflazacort or prednisolone and be on any dose regimen. Since glucocorticoid steroids are widely used in ambulant boys from an early age until late into teenage and even adult years, this study will not take age and ambulatory status into account and will only exclude patients that need daytime ventilator assistance. The schedule of assessments will include a Screening Visit and up to 9 protocol visits, including a Follow-up Visit. A Screening Visit will take place a maximum of 4 weeks prior to the Baseline Visit (Visit 1, study day -1). Beginning at Baseline, the patient will receive study medication to be taken at home, and will undergo regular assessments in the clinic throughout the study period until Visit 8 at Week 78 at which time the study will be completed and medication discontinued. All patients completing Visit 8/Week 78, and considered eligible by the Investigator will be able to participate in an open-label extension study (SIDEROS-E) and will continue to receive idebenone until idebenone is commercially available for patients included in the study or SIDEROS-E is terminated by the Sponsor, whichever occurs first. The duration of the SIDEROS-E study will be defined in a separate protocol. For all patients not participating in the extension study (SIDEROS-E), a Follow-up Visit (Visit 9/Follow-up Visit) will take place 4 weeks after end of Treatment at Visit 8/Week 78 or after premature discontinuation of study medication. Each hospital visit will include efficacy assessments (respiratory function assessed by hospital-based spirometry, oxygen saturation, end-tidal CO2) and safety assessments (adverse events, concomitant medication, physical examination, vital signs, safety laboratory evaluations). In addition, respiratory function will be assessed weekly at home with a hand-held device in order to closely monitor respiratory function between hospital visits. The study medication, all medical procedures and laboratory testing, and the visits to the study centre are free of charge. In addition the patients will receive a travel allowance to cover reasonable expenses to and from the study centre. Participants will not otherwise be compensated for this study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02814019
Study type Interventional
Source Santhera Pharmaceuticals
Contact
Status Terminated
Phase Phase 3
Start date September 2016
Completion date December 1, 2020

See also
  Status Clinical Trial Phase
Completed NCT01478022 - To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20 Phase 1
Completed NCT00654784 - Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy Phase 2
Recruiting NCT02614820 - The Safety, Efficacy and Tolerability of Remote Ischemic Preconditioning as a Therapy to DMD N/A
Withdrawn NCT02036463 - A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy Phase 2
Completed NCT02255552 - Study of Eteplirsen in DMD Patients Phase 3
Completed NCT01982695 - Cardiomyopathy in DMD: Lisinopril vs. Losartan N/A
Recruiting NCT05516745 - E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home" N/A
Completed NCT02420379 - Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy Phase 2
Active, not recruiting NCT05135663 - Extension Study of NS-089/NCNP-02 in DMD Phase 2
Completed NCT01380964 - Research of Biomarkers in Duchenne Muscular Dystrophy Patients N/A
Completed NCT05990608 - Peabody Developmental Motor Scaling In Children With Period Duchenne Muscular Dystrophy
Recruiting NCT04322357 - Twice Weekly Steroids and Exercise as Therapy for DMD Phase 2
Not yet recruiting NCT06392724 - A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy. Early Phase 1
Completed NCT01540409 - Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Phase 2
Terminated NCT04184882 - A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD) Phase 1
Terminated NCT04254172 - A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy
Recruiting NCT05524883 - Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Phase 1/Phase 2
Completed NCT01761292 - A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD Phase 1/Phase 2